Scholar Rock (Nasdaq: SRRK) has unveiled encouraging Phase II data for its experimental therapy apitegromab, showing the drug ...

Ozempic is an FDA-approved medication for people with type 2 diabetes. It’s often prescribed off-label for weight loss — that ...

Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...

There is a high demand for weight loss drugs in the US [] A huge surge in Ireland's goods exports in the first quarter of ...

While there is still some uncertainty in the market related to tariffs, the U.S. economy, and a new conflict in the Middle ...

In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...

Some individuals living with obesity and overweight may find it difficult to embark on a weight loss journey alone. It’s not ...

Scholar Rock said its investigational therapy helped preserve lean mass among patients taking a powerful weight loss drug.

Scholar Rock said on Wednesday a combination of its experimental drug and Eli Lilly's weight-loss treatment Zepbound helped overweight patients preserve significantly more lean mass in a mid-stage ...

A federal judge in Texas has upheld the U.S. Food and Drug Administration's decision to remove Novo Nordisk's blockbuster drugs Ozempic and Wegovy from the drug shortage list, rejecting a challenge ...

Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a ...

Scholar Rock's latest trial returned very positive results. Shares of Scholar Rock Holding (NASDAQ: SRRK) are soaring today, ...